Which has better valuation and earnings, OKUR or KYTX?

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A

Is OKUR or KYTX more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Kyverna Therapeutics N/A -81.92% -63.74%

Which has higher earnings & valuation, OKUR or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is OKUR or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% AgomAb Therapeutics N/A N/A N/A

OnKure Therapeutics (OKUR) Competitors

$2.94 -0.16 (-5.16%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.95 +0.01 (+0.34%)

As of 05:30 AM Eastern

Compare

OKUR vs. KMDA, PBYI, PRTA, KYTX, and AGMB

Should you buy OnKure Therapeutics stock or one of its competitors? OnKure Therapeutics's main competitors and comparable companies include Kamada (KMDA), Puma Biotechnology (PBYI), Prothena (PRTA), Kyverna Therapeutics (KYTX), and AgomAb Therapeutics (AGMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OnKure Therapeutics compare to Kamada?

OnKure Therapeutics (NASDAQ:OKUR) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Kamada has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Kamada	$180.46M	2.79	$20.20M	$0.38	23.08

OnKure Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Kamada has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

OnKure Therapeutics currently has a consensus target price of $17.50, suggesting a potential upside of 495.24%. Kamada has a consensus target price of $13.50, suggesting a potential upside of 53.93%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to OnKure Therapeutics' net margin of 0.00%. Kamada's return on equity of 8.37% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Kamada	11.60%	8.37%	5.85%

In the previous week, Kamada had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for Kamada and 2 mentions for OnKure Therapeutics. Kamada's average media sentiment score of 0.56 beat OnKure Therapeutics' score of -1.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
OnKure Therapeutics	Negative
Kamada	Positive

Summary

Kamada beats OnKure Therapeutics on 13 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Puma Biotechnology has a net margin of 11.50% compared to OnKure Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
OnKure Therapeutics	N/A	-49.01%	-45.77%

In the previous week, Puma Biotechnology had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Puma Biotechnology and 2 mentions for OnKure Therapeutics. Puma Biotechnology's average media sentiment score of 0.34 beat OnKure Therapeutics' score of -1.00 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Neutral
OnKure Therapeutics	Negative

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.10	$31.11M	$0.52	17.85
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Puma Biotechnology currently has a consensus target price of $6.00, suggesting a potential downside of 35.34%. OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 495.24%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Puma Biotechnology beats OnKure Therapeutics on 11 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Prothena?

OnKure Therapeutics (NASDAQ:OKUR) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

OnKure Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 495.24%. Prothena has a consensus price target of $24.57, indicating a potential upside of 183.08%. Given OnKure Therapeutics' higher possible upside, equities analysts plainly believe OnKure Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

OnKure Therapeutics has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Prothena	$9.68M	46.94	-$244.09M	-$0.84	N/A

In the previous week, Prothena had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Prothena and 2 mentions for OnKure Therapeutics. Prothena's average media sentiment score of 1.18 beat OnKure Therapeutics' score of -1.00 indicating that Prothena is being referred to more favorably in the news media.

Company	Overall Sentiment
OnKure Therapeutics	Negative
Prothena	Positive

OnKure Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Prothena	-80.68%	-16.45%	-14.51%

OnKure Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Prothena has a beta of -0.33, meaning that its share price is 133% less volatile than the broader market.

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Prothena beats OnKure Therapeutics on 11 of the 16 factors compared between the two stocks.

How does OnKure Therapeutics compare to Kyverna Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

OnKure Therapeutics' return on equity of -49.01% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

OnKure Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

OnKure Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 495.24%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 324.33%. Given OnKure Therapeutics' higher probable upside, research analysts clearly believe OnKure Therapeutics is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

In the previous week, Kyverna Therapeutics had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Kyverna Therapeutics and 2 mentions for OnKure Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.00 beat OnKure Therapeutics' score of -1.00 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
OnKure Therapeutics	Negative
Kyverna Therapeutics	Neutral

Summary

Kyverna Therapeutics beats OnKure Therapeutics on 7 of the 13 factors compared between the two stocks.

How does OnKure Therapeutics compare to AgomAb Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 2 articles in the media. AgomAb Therapeutics' average media sentiment score of 0.00 beat OnKure Therapeutics' score of -1.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
OnKure Therapeutics	Negative
AgomAb Therapeutics	Neutral

AgomAb Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
AgomAb Therapeutics	N/A	N/A	N/A

91.0% of OnKure Therapeutics shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

OnKure Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 495.24%. AgomAb Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 248.19%. Given OnKure Therapeutics' higher probable upside, research analysts plainly believe OnKure Therapeutics is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

AgomAb Therapeutics beats OnKure Therapeutics on 5 of the 9 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$125.23M	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.84	13.88	274.10	25.70
Price / Sales	N/A	1,437.48	672.61	90.85
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.72	15.45	10.48	6.32
Net Income	-$59.52M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-0.68%	-1.68%	-0.68%	0.17%
1 Month Performance	-24.42%	-6.15%	-3.18%	-3.27%
1 Year Performance	13.08%	30.67%	15.13%	5.58%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	2.5358 of 5 stars	$2.94 -5.2%	$17.50 +495.2%	+16.2%	$125.23M	N/A	N/A	45	Positive News Analyst Upgrade
KMDA Kamada	4.9716 of 5 stars	$8.09 -2.6%	$13.00 +60.7%	+26.7%	$477.87M	$191.85M	21.29	462	Analyst Forecast
PBYI Puma Biotechnology	1.2076 of 5 stars	$9.25 +1.2%	$6.00 -35.1%	+97.0%	$471.81M	$228.40M	17.79	179
PRTA Prothena	3.3946 of 5 stars	$8.33 -6.0%	$24.57 +195.0%	+4.5%	$463.85M	$54.53M	N/A	67	Positive News Insider Trade
KYTX Kyverna Therapeutics	1.4625 of 5 stars	$6.96 -5.9%	$30.00 +331.0%	+12.0%	$457.64M	N/A	N/A	149	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. KMDA, PBYI, PRTA, KYTX, and AGMB

How does OnKure Therapeutics compare to Kamada?

Summary

How does OnKure Therapeutics compare to Puma Biotechnology?

Summary

How does OnKure Therapeutics compare to Prothena?

Summary

How does OnKure Therapeutics compare to Kyverna Therapeutics?

Summary

How does OnKure Therapeutics compare to AgomAb Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. KMDA, PBYI, PRTA, KYTX, and AGMB

How does OnKure Therapeutics compare to Kamada?

Which has stronger valuation and earnings, OKUR or KMDA?

Which has more risk & volatility, OKUR or KMDA?

Do analysts prefer OKUR or KMDA?

Do insiders & institutionals hold more shares of OKUR or KMDA?

Is OKUR or KMDA more profitable?

Does the media prefer OKUR or KMDA?

Summary

How does OnKure Therapeutics compare to Puma Biotechnology?

Which has more volatility and risk, PBYI or OKUR?

Is PBYI or OKUR more profitable?

Does the media favor PBYI or OKUR?

Do institutionals & insiders hold more shares of PBYI or OKUR?

Which has higher valuation & earnings, PBYI or OKUR?

Do analysts prefer PBYI or OKUR?

Summary

How does OnKure Therapeutics compare to Prothena?

Do analysts recommend OKUR or PRTA?

Which has higher valuation and earnings, OKUR or PRTA?

Does the media refer more to OKUR or PRTA?

Is OKUR or PRTA more profitable?

Which has more volatility & risk, OKUR or PRTA?

Do institutionals & insiders believe in OKUR or PRTA?

Summary

How does OnKure Therapeutics compare to Kyverna Therapeutics?

Is OKUR or KYTX more profitable?

Which has more risk & volatility, OKUR or KYTX?

Do institutionals and insiders have more ownership in OKUR or KYTX?

Do analysts rate OKUR or KYTX?

Which has better valuation and earnings, OKUR or KYTX?

Does the media refer more to OKUR or KYTX?

Summary

How does OnKure Therapeutics compare to AgomAb Therapeutics?

Does the media prefer OKUR or AGMB?

Is OKUR or AGMB more profitable?

Do institutionals & insiders hold more shares of OKUR or AGMB?

Which has higher earnings & valuation, OKUR or AGMB?

Do analysts prefer OKUR or AGMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools